Latest Syndax News & Updates

See the latest news and media coverage for Syndax. We track all announcements, press releases, and industry mentions in real time, all in one place.

Syndax

Commercial-stage biopharmaceutical company developing targeted cancer therapies

Last updated Yesterday

Latest news about Syndax

In short: Syndax reported Q2 2026 revenue of $72.8M, unveiled new pipeline assets at its R&D Day, and raised $250M via convertible notes.

July 7 Syndax

The R&D event features SNDX-4321, a novel EGFR inhibitor, and SNDX-62122, a next-generation menin inhibitor, with Phase 2 IPF data expected in 4Q26.

June 11 Syndax

The all-oral regimen showed 88% ORR and 71% CRc in relapsed/refractory AML.

June 11 Syndax

Data show high response rates in multiple acute leukemia subtypes and settings, including real-world and frontline combinations.

June 4 Syndax

The 2.25% notes mature in 2031, and net proceeds of ~$243M will fund R&D, commercialization, and business development.

Yesterday Yahoo Finance

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage...

Yesterday Reuters

Syndax Pharmaceuticals said on Monday it will stop developing a treatment for idiopathic pulmonary f...

September 10 Traders Union

Syndax Pharmaceuticals stock falls 7% today, trading at $18.47. Traders monitor potential trend shifts while awaiting new ...

August 12 Yahoo Finance

Syndax Pharmaceuticals (NASDAQ:SNDX) just posted a quarter that nearly doubled revenue, yet shares...

Never miss news about Syndax

Track Syndax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Syndax and other trending companies.